Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry.
[en] BACKGROUND: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare vascular tumor which has an intermediate aggressive behavior. Although the value of liver transplantation (LT) is well established, its place in the management of HEHE is still unclear. The aim of this study is to confirm, based on a very large patient cohort, the value of LT in the management of HEHE and to identify risk factors for post-LT recurrence. METHODS: The outcome of 149 transplant recipients with HEHE recorded in the European Liver Transplant Registry during the period November 1984 to May 2014 was analyzed. Median post-LT follow-up was 7.6 years (interquartile range, 2.8-14.4). RESULTS: Cox regression analysis showed that macrovascular invasion (hazard ratio [HR], 4.8; P < 0.001), pre-LT waiting time of 120 days or less (HR, 2.6; P = 0.01) and hilar lymph node invasion (HR = 2.2; P = 0.03), but not pre-LT extrahepatic disease, were significant risk factors for recurrence. These findings, which were also confirmed in a propensity score analysis, allowed the development of a HEHE-LT score enabling stratification of patients in relation to their risk of tumor recurrence. Patients with a score of 2 or less had a much better 5-year disease-free survival compared to those having a score of 6 or higher (93.9% vs 38.5%; P < 0.001). CONCLUSIONS: The analysis of this (largest in the world) HEHE adult liver recipient cohort clearly confirms the value of LT in the treatment of this rare disorder and also permits identification of patients at risk of posttransplant recurrence. Posttransplant follow-up should take the HEHE-LT score into account. Extrahepatic disease localization is reconfirmed not to be a contraindication for LT.
Disciplines :
Surgery Oncology Gastroenterology & hepatology
Author, co-author :
Lai, Quirino; 1 Starzl Abdominal Transplant Unit, University Hospitals St. Luc, Université
Feys, Estelle
Karam, Vincent
Adam, Rene
Klempnauer, Jurgen
Oliverius, Martin
Mazzaferro, Vincenzo
Pascher, Andreas
Remiszewski, Piotr
Isoniemi, Helena
Pirenne, Jacques
Foss, Aksel
Ericzon, Bo G
Markovic, Sasa
Lerut, Jan P
European Liver Intestine Transplant Association, ( E L I T A)
Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry.
IshakKG, Sesterhenn IA,GoodmanZD, et al. Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum Pathol. 1984;15:839-852.
Dean P, Haggitt R, O'Hara C. Malignant epithelioid hemangioendothelioma of the liver in young women. Relationship to oral contraceptive use. Am J Surg Pathol. 1985;9:695-704.
Grotz TE, NagorneyD,Donohue J, et al. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? HPB (Oxford). 2010;12:546-553.
Lerut JP, Orlando G, AdamR, et al. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: Report of the European Liver Transplant Registry. Ann Surg. 2007;246:949-957; discussion 957.
Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer. 1999;85: 562-582.
Ben-Haim M, Roayaie S, Ye MQ, et al. Hepatic epithelioid hemangioendothelioma: resection or transplantation, which and when? Liver Transpl Surg. 1999;5:526-531.
Imanishi H, Kawata M, Yanagihara M, et al. Epithelioid hemangioendothelioma of the liver associated with thrombocytopenia and coagulopathy. Hepatogastroenterology. 2002;49:1673-1675.
Lerut JP, Orlando G, Sempoux C, et al. Hepatic haemangioendothelioma in adults: excellent outcome following liver transplantation. Transpl Int. 2004;17:202-207.
Madariaga JR, Marino IR, Karavias DD, et al. Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma. Ann Surg Oncol. 1995;2:483-487.
Marino IR, Todo S, TzakisAG. Treatment of hepatic epithelioid hemangioendothelioma with liver transplantation. Cancer. 1988;62:2079-2084.
Rodriguez JA, Becker NS, O'Mahony CA, et al. Long-term outcomes following liver transplantation for hepatic hemangioendothelioma: the UNOS experience from 1987 to 2005. J Gastrointest Surg. 2008;12:110-116.
Nudo CG, Yoshida EM, Bain VG, et al. Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol. 2008;22:821-824.
Mehrabi A, Kashfi A, Fonouni H, et al. Primarymalignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107:2108-2121.
Dietze O, Davies SE, Williams R, et al. Malignant epithelioid haemangioendothelioma of the liver: a clinicopathologic and histochemical study of 12 cases. Histopathology. 1989;15:225-237.
Otrock ZK, Al-Kutoubi A, KattarMM, et al. Spontaneous complete regression of hepatic epithelioid haemangioendothelioma. Lancet Oncol. 2006; 7:439-441.
Komatsu Y, Koizumi T, Yasuo M, et al. Malignant hepatic epithelioid hemangioendothelioma with rapid progression and fatal outcome. Intern Med. 2010;49:1149-1153.
Theurillat JP, Vavricka SR,Went P, et al. Morphologic changes and altered gene expression in an epithelioid hemangioendothelioma during a tenyear course of disease. Pathol Res Pract. 2003;199:165-170.
Lyburn ID, TorreggianiWC, Harris AC, et al. Hepatic epithelioid hemangioendothelioma: sonographic, CT, and MR imaging appearances. Am J Roentgenol. 2003;180:1359-1364.
St Peter SD, Moss AA, Huettl EA, et al. Chemoembolization followed by orthotopic liver transplant for epithelioid hemangioendothelioma. Clin Transpl. 2003;17:549-553.
Zhao XY, Rakhda MI, Habib S, et al. Hepatic epithelioid hemangioendothelioma: a comparison ofWestern and Chinese methods with respect to diagnosis, treatment and outcome. Oncol Lett. 2014;7:977-983.
Thin LW, Wong DD, De Boer BW, et al. Hepatic epithelioid haemangioendothelioma: challenges in diagnosis and management. Intern Med J. 2010;40:710-715.
Zhou L, Cui MY, Xiong J, et al. Spectrum of appearances on CTand MRI of hepatic epithelioid hemangioendothelioma. BMC Gastroenterol. 2015;15:69.
Kitapci MT, Akka? BE, Gullu I, et al. FDG-PET/CT in the evaluation of epithelioid hemangioendothelioma of the liver: the role of dual-time-point imaging. A case presentation and review of the literature. Ann Nucl Med. 2010;24:549-553.
Nguyen BD. Epithelioid hemangioendothelioma of the liver with F-18 FDG PET imaging. Clin Nucl Med. 2004;29:828-830.
Thomas RM, Aloia TA, Truty MJ, et al. Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma. HPB (Oxford). 2014;16: 677-685.
Orlando G, Adam R, Mirza D, et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation-the European Liver Transplant Registry experience. Transplantation. 2013;95:872-877.
KelleherMB, Iwatsuki S, Sheahan DG. Epithelioid hemangioendothelioma of liver. Clinicopathological correlation of 10 cases treated by orthotopic liver transplantation. Am J Surg Pathol. 1989;13:999-1008.
Demetris AJ, MinerviniM, Raikow RB, et al. Hepatic epithelioid hemangioendothelioma: biological questions based on pattern of recurrence in an allograft and tumor immunophenotype. Am J Surg Pathol. 1997;21: 263-270.
Soslow RA, Yin P, Steinberg CR, et al. Cytopathologic features of hepatic epithelioid hemangioendothelioma. Diagn Cytopathol. 1997;17:50-53.
Calabrò L, Di Giacomo AM, AltomonteM, et al. Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res. 2007;26:145-150.
Emamaullee JA, Edgar R, Toso C, et al. Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management. Liver Transpl. 2010;16:191-197.
Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119:2639-2644.
AgulnikM, Yarber JL, Okuno SH, et al. An open-label,multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257-263.
Lau A, Malangone S, Green M, et al. Combination capecitabine and bevacizumab in the treatment of metastatic hepatic epithelioid hemangioendothelioma. Ther Adv Med Oncol. 2015;7:229-236.
Desie N, Van Raemdonck DE, Ceulemans LJ, et al. Combined or serial liver and lung transplantation for epithelioid hemangioendothelioma: a case series. Am J Transplant. 2015;15:3247-3254.
Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50: 644-653.
Errani C, Sung YS, Zhang L, et al. Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet. 2012;205:12-17.
Kayler LK, Merion RM, Arenas JD, et al. Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. Transplantation. 2002;74: 128-130.
Mascarenhas RC, Sanghvi AN, Friedlander L, et al. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology. 2004;67:471-475.
Kelly H, O'Neil BH. Response of epithelioid haemangioendothelioma to liposomal doxorubicin. Lancet Oncol. 2005;6:813-815.
Lakkis Z, Kim S, Delabrousse E, et al. Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma. J Hepatol. 2013;58:1254-1257.
Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775-784.
Flucke U, Vogels RJ, de Saint Aubain Somerhausen N, et al. Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagn Pathol. 2014;9:131.